- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- August 2018
- 86 Pages
Global
From €9641EUR$10,000USD£8,245GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- April 2023
- 108 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Drug Pipelines
- July 2018
- 616 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- January 2022
- 220 Pages
Global
From €5947EUR$6,168USD£5,086GBP
Remicade is a biologic drug used to treat immune disorders such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Remicade is administered intravenously and is usually given in a series of three infusions over a period of several weeks.
Remicade is a major player in the immune disorders drugs market, with a wide range of indications and a long track record of safety and efficacy. It is one of the most widely prescribed biologic drugs in the world, and is used by millions of patients.
Companies in the Remicade market include Johnson & Johnson, Merck, Pfizer, AbbVie, and Amgen. Show Less Read more